Article Sidebar

PDF
Date Published: 31/07/2022
Abstract Views: 198
Views PDF: 202
DOI: https://doi.org/10.51298/vmj.v516i2.3100
Issue
Vol. 516 No. 2 (2022)
Section
Các bài báo
How to Cite
Ngọc Yến Nhi, V. ., & Thị Thu Thủy, N. . (2022). WILLINGNESS-TO-PAY PER QUALITY-ADJUSTED LIFE YEAR OF PATIENTS WITH HEMOPHILIA A IN NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION IN 2022. Vietnam Medical Journal, 516(2). https://doi.org/10.51298/vmj.v516i2.3100

WILLINGNESS-TO-PAY PER QUALITY-ADJUSTED LIFE YEAR OF PATIENTS WITH HEMOPHILIA A IN NATIONAL INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION IN 2022

Võ Ngọc Yến Nhi1, Nguyễn Thị Thu Thủy1,
1 University of Medicine and Pharmacy at Ho Chi Minh City

Main Article Content

Abstract

Hemophilia A is a prevalent coagulation disorder with high treatment expenses that places a significant financial burden on individuals, families, and society. Therefore, acessing the willingness to pay for this illness is crucial to take patients' accessibility into account and provide the required support measures. The study was carried out at the National Institute of Hematology and Blood Transfusion between 10/2021 and 06/2022. The study surveyed 194 patients with a male rate of 100%. The mean value of hemophilia A patients' willingness to pay per quality-adjusted life year (WTP/QALY) is 164.841.827,72 VND/QALY (95%CI: 118.514.386,40 - 211.169.269,03 VND/QALY). Relevant factors affecting the patient's WTP/QALY include marital status, education level, living place, health insurance benefits, age, disease level, quality of life coefficient as measured by the EQ-5D-5L and VAS scale.

Article Details

Keywords

willingness-to-pay, quality-adjusted life year, the National Institute of Hematology and Blood Transfusion, hemophilia A

References

1. Mansouritorghabeh Hassan (2015), "Clinical and laboratory approaches to hemophilia a", Iranian journal of medical sciences. 40 (3), pp. 194-205.
2. Tế Bộ Y (2016), về việc ban hành tài liệu chuyên môn “hướng dẫn chẩn đoán và điều trị bệnh hemophilia sửa đổi, bổ sung”, Bộ Y tế.
3. O’Hara Jamie et al. (2018), "The relationship between target joints and direct resource use in severe haemophilia", Health Economics Review. 8 (1), pp. 1-7.
4. Carlsson K Steen et al. (2004), "Willingness to pay for on‐demand and prophylactic treatment for severe haemophilia in Sweden", Haemophilia. 10 (5), pp. 527-541.
5. Chaugule Shraddha S. et al. (2015), "Understanding patient preferences and willingness to pay for hemophilia therapies", Patient preference and adherence. 9, pp. 1623-1630.
6. Oppe Mark et al. (2007), EQ-5D value sets: inventory, comparative review and user guide, Springer.
7. Martín-Fernández Jesus et al. (2014), "Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences". 14 (1), pp. 287.
8. Mai Vu Quynh et al. (2020), "An EQ-5D-5L Value Set for Vietnam", Quality of Life Research, pp. 1-11.
9. Gersten Todd (2020), Hemophilia A, https://medlineplus.gov/ency/article/000538.htm
10. Tổng cục thống kê (2020), Niên giám thống kê, https://www.gso.gov.vn/wp-content/ uploads/2021/07/Nien-giam-Tom-Tat-2020Ban-quyen.pdf
11. Phan Gia Huy (2019), "Phân tích ngưỡng chi trả cho 1 năm sống có chất lượng của người bệnh u lympho không hodgkin tại một số Bệnh viện thành phố Hồ Chí Minh/Phan Gia Huy".